Navigation Links
Phase 3 Cystic Fibrosis Trial Results Presented at European Conference
Date:6/15/2009

ek 26 with Bronchitol (p=0.001). Again, there was an immediate and sustained improvement in FEV1 over the 26 week period of the study (p=0.003). -- While the study was not powered to show a reduction in the secondary endpoint of exacerbation, the rate of a protocol defined pulmonary exacerbation (PDPE) per subject for the 26 weeks was lower for Bronchitol versus control: overall reduction in rate of 25% (p=0.2). -- There was a non significant increase in time to first PDPE (p=0.1) for the Intention to Treat group, however, for the Per Protocol population, i.e. those who were mostly compliant with therapy and stayed in the study, there was a significant increase in time to first PDPE (p=0.026). -- There was a clinically meaningful change from baseline (129mL) and control (113mL) at week 26 with Bronchitol for Forced Vital Capacity (FVC) of the lung (p=0.002). Additionally, treatment with Bronchitol showed an immediate and sustained improvement in lung capacity (FVC) over the 26 week treatment period (p<0.001). Safety -- There was a similar number of adverse events and serious adverse events per treatment group, with no deaths in the study. -- Respiratory adverse events that were more common with Bronchitol compared with placebo, included cough (25.4% versus 20.3%), haemoptysis (11.9% versus 8.5%) and pharyngolaryngeal pain (13.6% versus 4.2%). -- There were similar rates between the groups for adverse events of particular interest including: wheezing, asthma, bronchospasm (Bronchitol 4.5% versus 5.9%). -- At screening 7% of patients were ineligible to participate due to suspected undiagnosed hyperreactive airway disease. -- Overall infections were lower in the Bronchitol group (39% versus 47.5%). -- There was no difference in microbial growth for specifi
'/>"/>
SOURCE Pharmaxis Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
6. Phase III Trial Finds Pharmaxis Bronchitol Effective
7. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
8. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
9. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
10. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
11. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Marktech Optoelectronics has introduced the MTE280xxx ... in the 280 nm wavelength range. This series joins ... from 280nm to 405nm. These new devices are suitable ... as curing. Mark Campito, Marktech’s CEO states that “what ... manufacturers is that we offer it in one of ...
(Date:9/22/2014)... who were treated with a statin in the hospital ... likely to survive than those who were not, according ... . This study was conducted by the same researchers ... can improve survival in victims of ischemic stroke., Ischemic ... a blood vessel that blocks blood from reaching areas ...
(Date:9/22/2014)... job it is to stop bleeding, are very simple. ... "feel" the physical environment around them, researchers at Emory ... surfaces with greater stiffness by increasing their stickiness, the ... other components of the clotting system, the researchers found. ... for, in that they are able to sense the ...
(Date:9/22/2014)... D.C. (PRWEB) September 22, 2014 ... Georgetown President John DeGioia on Friday renewed their ... for an additional five years to expand the ... biosecurity, nonproliferation and global climate, energy and environmental ... of an MOU originally signed in December 2009 ...
Breaking Biology Technology:Marktech Introduces its New Line of Deep UV Emitters 2Statin use during hospitalization for hemorrhagic stroke associated with improved survival 2Platelets modulate clotting behavior by 'feeling' their surroundings 2Lawrence Livermore Renews Pact with Georgetown University to Expand Research and Education in Science and Policy 2
... and PHILADELPHIA, July 4 ,Shire Limited (LSE:SHP, NASDAQ: SHPGY), ... earnings on,Thursday 31 July 2008, Results press ... BST / 07:00 EDT Investor meeting and conference ... Investor & Analyst meeting and conference call:, Angus ...
... Research Group has,released results from aboratory testing ... at Oregon State University which,demonstrated the Eniva ... for human cells. This third party testing ... effort to further identify,mechanisms by which the ...
... Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS) today announced that ... its cash burn rate. As previously,announced, the Company ... acquisitions and mergers. In conjunction with this,process, the ... its VP,series of drugs, and has determined that ...
Cached Biology Technology:Shire Ltd - Second Quarter 2008 Results Date Notification - 31 July 2008 2Eniva VIBE(R) Nutraceutical Tested at Linus Pauling Micronutrient Research Institute and Found to Possess DNA Protective Properties 2Vasogen Provides Corporate Update 2
(Date:9/23/2014)... DNA fragments called "jumping genes" that insert themselves into ... that phenomenon can result in age-related diseases such as ... report that the "jumping genes" in mice become active ... keeping them in check in order to take on ... in Nature Communications , Professor of Biology Vera ...
(Date:9/22/2014)... that after a long stay in the Intensive Care ... remain behind in patients, intestines. The team tested these ... when provoked by conditions that mimic the body,s stress ... mBio , the online open-access journal of the American ... treatment of ICU patients who can develop a life-threatening ...
(Date:9/22/2014)... September 23, 2014 A new American Cancer ... Nutrition Assistance Program (SNAP), previously known as the ... compared with income eligible non-participants. The authors say ... aimed at enhancing the dietary quality of SNAP ... low-income individuals and households with the resources to ...
Breaking Biology News(10 mins):A multi-function protein is key to stopping genomic parasites from 'jumping' 2Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 2Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 3Federal food program puts food on the table, but dietary quality could be improved 2
... Hidenori Ichijo and Hideki Nishitoh (The University of Tokyo) ... genetics of ALS. Amyotrophic lateral sclerosis (ALS), also ... fatal neurological disease involving the degeneration and death of ... the most common neuromuscular diseases worldwide, affecting as roughly ...
... sturgeons, more caviar will be exported from Caspian Sea ... of unacceptably permissive new trade quotas announced Thursday by ... Most sturgeon species are endangered and some, like beluga ... damage this ancient fish,s chance of recovery and survival, ...
... New research* shows that while engineered nanomaterials can ... food chain from single celled organisms to higher ... and there was no evidence of the nanomaterials ... results observed by researchers from the National Institute ...
Cached Biology News:New CITES quotas allow more caviar export, further jeopardize endangered sturgeon 2New CITES quotas allow more caviar export, further jeopardize endangered sturgeon 3New CITES quotas allow more caviar export, further jeopardize endangered sturgeon 4Research measures movement of nanomaterials in simple model food chain 2
Request Info...
These macrocarriers are for the biolistic PDS-1000 He and Hepta systems. Supplied as 500 macrocarriers....
... 211 ] affinity isolated antibody aqueous solution ... (without Mg 2+ and Ca 2+ ), ... protease free) and 0.05% sodium azide. a synthetic ... Hck that contains tyrosine 207 and serine 209 ...
High voltage electrophoresis power supply...
Biology Products: